35160-11-3

Basic information

• Product Name: 2-Thiazolamine, 4,5-dihydro-N-[2-(trifluoromethyl)phenyl]-
• CAS NO: 35160-11-3
• Molecular Formula: C10H9F3N2S
• Molecular Weight: 246.256
• Mol File: 35160-11-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-Thiazolamine, 4,5-dihydro-N-[2-(trifluoromethyl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Thiazolamine, 4,5-dihydro-N-[2-(trifluoromethyl)phenyl]-(35160-11-3)
• EPA Substance Registry System: 2-Thiazolamine, 4,5-dihydro-N-[2-(trifluoromethyl)phenyl]-(35160-11-3)

Safety Data

• Hazardous Substances Data: 35160-11-3(Hazardous Substances Data)

Upstream product

• 63494-72-4 N-((2-(trifluoromethyl)phenyl)carbamothioyl)benzamide 
• 107-09-5 2-bromoethylamine 
• 1736-71-6 2-trifluoromethylphenyl thiourea 
• 88-17-5 2-(trifluoromethyl)benzenamine 
• 2576-47-8 2-bromoethylamine hydrobromide 

Downstream Products

• 1391724-85-8 C₂₅H₃₁F₃N₂O₂S₂ 
• 1391724-86-9 C₁₆H₁₂F₄N₂O₂S₂ 
• 1391724-84-7 C₁₆H₁₁Cl₂F₃N₂O₂S₂ 
• 1391724-82-5 C₁₇H₁₂F₆N₂O₂S₂ 
• 1391724-88-1 C₁₇H₁₅F₃N₂O₂S₂ 
• 1391724-87-0 C₂₀H₁₅F₃N₂O₂S₂ 
• 1391724-83-6 C₁₆H₁₂F₃N₃O₄S₂ 

Relevant articles and documents

Discovery of Novel Thiazol-2-Amines and Their Analogues as Bioactive Molecules: Design, Synthesis, Docking and Biological Evaluation

A simple and highly efficient procedure for the synthesis of novel thiazol-2-amines, via Mannich reaction with secondary amines, is described. The newly synthesized derivatives 8(a-e) and 9(a-e) were characterized by 1 H NMR, 13 C NMR, IR, Mass spectroscopy and elemental analysis. All the derivatives were evaluated for their in-vitro anti-microbial activity against a panel of pathogenic strains of bacteria and fungi. The SAR showed that the secondary amines had a significant impact on the in-vitro antimicrobial activity of this class of agents. The most potent analogue N-((1H-benzo[d]imidazol-1-yl)methyl)-N-(2(trifluoromethyl)phenyl)-4,5-dihydrothiazol-2-amine (8c) showed excellent inhibition with MIC (zoi) 6.25 (22.5), 25 (21.5) and 25 (18) μg/mL against E. coli, S. typhi and P. aeruginosa respectively as compared to the standard drug. Molecular docking results suggest that compound exhibited inhibitory activity by binding of the title compound within the active sites of the inhibiting Enoyl ACP reductase, Lipid A, Pyridoxal kinase and type I DHQase enzymes. The compound exhibited promising anti-microbial activity which can be further explored as potential lead for the development of cheaper, safe, effective and potent drugs against resistant microbial parasites.

Synthesis and QSAR studies in 2-(N-aryl-N-aroyl)amino-4,5-dihydrothiazole derivatives as potential antithrombotic agents

A series of 2-(N-aryl-N-aroyl)amino-4,5-dihydrothiazole derivatives have been synthesized via cyclocondensation of N-aryl thioureas with 2-bromoethylamine hydrobromide followed by the reaction of the product thus obtained with aroyl chlorides. Title compounds were evaluated for their antithrombotic activity in vivo in mice where one of these compound 29 provided 65% protection as compared to 77% protection offered by the standard Indomethacin. Quantitative Structure-Activity Relationship (QSAR) studies were performed on these compounds using physicochemical (hydrophobic, electronic, steric) parameter as independent and antithrombic activity as dependent parameter, where antithrombotic activity correlated best (r > 0.8) with electronic parameters (F, σ or μ) having high statistical significance > 99.9% (F2,22 > 15.0; F2,22α:0.001 = 11.0) suggesting that hydrophobic, steric and resonance factors are insignificant in this set of molecules for the activity.